DK166805B1 - Threo-isomeren af 3'-azido-3'-deoxythymidin til anvendelse ved behandling af eller profylakse for humane retrovirusinfektioner, anvendelse af forbindelsen til fremstilling af et laegemiddel med naevnte indikation og farmaceutisk praeparat indeholdende forbindelsen - Google Patents

Threo-isomeren af 3'-azido-3'-deoxythymidin til anvendelse ved behandling af eller profylakse for humane retrovirusinfektioner, anvendelse af forbindelsen til fremstilling af et laegemiddel med naevnte indikation og farmaceutisk praeparat indeholdende forbindelsen Download PDF

Info

Publication number: DK166805B1
Authority: DK; Denmark
Prior art keywords: compound; azido; treatment; preparation; active ingredient
Prior art date: 1985-03-16

Application number

DK118286A

Other languages

Danish (da)

English (en)

Other versions

DK118286D0 (da

DK118286A (da

Inventor

Janet Litster Rideout

David Walter Barry

Sandra Nusinoff Lehrman

Clair Martha Heider St

Phillip Allen Furman

Iii Lowrie Miller Beacham

Harry Sidney Leblanc

George Andrew Freeman

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-03-16

Filing date

1986-03-14

Publication date

1993-07-19

1985-03-16 Priority claimed from GB858506868A external-priority patent/GB8506868D0/en

1985-03-16 Priority claimed from GB858506869A external-priority patent/GB8506869D0/en

1985-05-09 Priority claimed from GB858511774A external-priority patent/GB8511774D0/en

1985-05-09 Priority claimed from GB858511775A external-priority patent/GB8511775D0/en

1985-09-27 Priority claimed from GB858523881A external-priority patent/GB8523881D0/en

1986-03-14 Application filed by Wellcome Found filed Critical Wellcome Found

1986-03-14 Publication of DK118286D0 publication Critical patent/DK118286D0/da

1986-09-17 Publication of DK118286A publication Critical patent/DK118286A/da

1993-07-19 Application granted granted Critical

1993-07-19 Publication of DK166805B1 publication Critical patent/DK166805B1/da

Links

HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 title claims abstract description 10
150000001875 compounds Chemical class 0.000 title claims description 51
238000011282 treatment Methods 0.000 title claims description 19
208000005074 Retroviridae Infections Diseases 0.000 title claims description 4
238000002360 preparation method Methods 0.000 title description 26
239000000825 pharmaceutical preparation Substances 0.000 title description 2
229940126601 medicinal product Drugs 0.000 title 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 claims abstract description 8
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims abstract description 7
206010038997 Retroviral infections Diseases 0.000 claims abstract description 4
239000004480 active ingredient Substances 0.000 claims description 44
150000002148 esters Chemical class 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 13
238000011321 prophylaxis Methods 0.000 claims description 12
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 11
208000030507 AIDS Diseases 0.000 claims description 8
229940113082 thymine Drugs 0.000 claims description 7
208000031886 HIV Infections Diseases 0.000 claims description 5
208000037357 HIV infectious disease Diseases 0.000 claims description 5
208000005599 HTLV-I Infections Diseases 0.000 claims description 5
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
208000007687 HTLV-II Infections Diseases 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
208000027814 HTLV-2 infection Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
241000700605 Viruses Species 0.000 abstract description 15
208000032839 leukemia Diseases 0.000 abstract description 3
241001465754 Metazoa Species 0.000 abstract 2
241000282324 Felis Species 0.000 abstract 1
208000027096 gram-negative bacterial infections Diseases 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 description 23
-1 methanesulfonyl) Chemical class 0.000 description 16
239000000243 solution Substances 0.000 description 15
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
238000000034 method Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
239000003826 tablet Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000002585 base Substances 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
239000008101 lactose Substances 0.000 description 8
241001430294 unidentified retrovirus Species 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 7
230000008569 process Effects 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
239000007788 liquid Substances 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
229940069328 povidone Drugs 0.000 description 6
239000002243 precursor Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
229940079593 drug Drugs 0.000 description 5
230000000694 effects Effects 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
239000000725 suspension Substances 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
229940080313 sodium starch Drugs 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000450599 DNA viruses Species 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000007907 direct compression Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical group 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
239000005457 ice water Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000001388 Opportunistic Infections Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
239000002253 acid Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000003610 charcoal Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000006260 foam Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
239000006072 paste Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
241000894007 species Species 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical compound ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-M 3-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-M 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
244000144730 Amygdalus persica Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000014912 Central Nervous System Infections Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
206010013887 Dysarthria Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
IIQSLZFGYAIEOC-UHFFFAOYSA-N OCCOCC1=NC=C2NC=NC2=N1 Chemical compound OCCOCC1=NC=C2NC=NC2=N1 IIQSLZFGYAIEOC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
208000004209 confusion Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000007423 decrease Effects 0.000 description 1
MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
206010013395 disorientation Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000009520 phase I clinical trial Methods 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
229950010765 pivalate Drugs 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
GIZSHQYTTBQKOQ-UHFFFAOYSA-N threo-Syringoylglycerol Chemical compound COC1=CC(C(O)C(O)CO)=CC(OC)=C1O GIZSHQYTTBQKOQ-UHFFFAOYSA-N 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
125000005389 trialkylsiloxy group Chemical group 0.000 description 1
DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
229940102001 zinc bromide Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Hematology (AREA)
Virology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK118286A 1985-03-16 1986-03-14 Threo-isomeren af 3'-azido-3'-deoxythymidin til anvendelse ved behandling af eller profylakse for humane retrovirusinfektioner, anvendelse af forbindelsen til fremstilling af et laegemiddel med naevnte indikation og farmaceutisk praeparat indeholdende forbindelsen DK166805B1 (da)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
GB8506869		1985-03-16
GB858506868A GB8506868D0 (en)	1985-03-16	1985-03-16	Antibacterial compound
GB8506868		1985-03-16
GB858506869A GB8506869D0 (en)	1985-03-16	1985-03-16	Antiviral compound
GB858511774A GB8511774D0 (en)	1985-05-09	1985-05-09	Antiviral compounds
GB8511774		1985-05-09
GB8511775		1985-05-09
GB858511775A GB8511775D0 (en)	1985-05-09	1985-05-09	Antibacterial compounds
GB858523881A GB8523881D0 (en)	1985-09-27	1985-09-27	Antiviral compounds
GB8523881		1985-09-27

Publications (3)

Publication Number	Publication Date
DK118286D0 DK118286D0 (da)	1986-03-14
DK118286A DK118286A (da)	1986-09-17
DK166805B1 true DK166805B1 (da)	1993-07-19

Family

ID=27516577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK118286A DK166805B1 (da)	1985-03-16	1986-03-14	Threo-isomeren af 3'-azido-3'-deoxythymidin til anvendelse ved behandling af eller profylakse for humane retrovirusinfektioner, anvendelse af forbindelsen til fremstilling af et laegemiddel med naevnte indikation og farmaceutisk praeparat indeholdende forbindelsen

Country Status (9)

Country	Link
EP (1)	EP0199451B1 (de)
JP (1)	JPH0723314B2 (de)
AT (1)	ATE135011T1 (de)
AU (1)	AU578809B2 (de)
CA (1)	CA1285935C (de)
DE (1)	DE3650492T2 (de)
DK (1)	DK166805B1 (de)
IE (1)	IE73219B1 (de)
MY (1)	MY104069A (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6448392B1 (en) *	1985-03-06	2002-09-10	Chimerix, Inc.	Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) *	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
HU197209B (en) *	1985-03-16	1989-03-28	Wellcome Found	Process for producing pharmaceutical compositions containing 3'-azido-3'-deoxytimidine of antiviral activity againt human retrovirus
IL78158A (en) *	1985-03-16	1988-04-29	Wellcome Found	Pharmaceutical compositions containing 3'-azido-3'-deoxythymidine
US4916122A (en) *	1987-01-28	1990-04-10	University Of Georgia Research Foundation, Inc.	3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4841039A (en) *	1986-05-01	1989-06-20	Emory University	2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4880782A (en) *	1986-11-21	1989-11-14	Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V.	Method of treating viral infections in humans and compositions therefor
FI892451L (fi) *	1986-11-21	1989-05-19	Max Planck Gesellschaft	Foerfarande med vilket virusinfektioner i maenniskor kan skoetas och kompositioner anvaenda daeri.
US5190926A (en) *	1987-01-28	1993-03-02	University Of Georgia Research Foundation, Inc.	3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
DK140588A (da) *	1987-03-16	1988-09-17	Wellcome Found	Terapeutisk nucleosider
EP0286825A3 (de) *	1987-03-18	1989-04-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Verwendung von 3'-fluro-3'-deoxythymidine zur Herstellung von medicamenten zur Behandlung von Viruskrankheiten
GB8707421D0 (en) *	1987-03-27	1987-04-29	Wellcome Found	Pharmaceutical formulations
EP0516186A3 (en) *	1987-04-16	1993-01-13	Medivir Aktiebolag	Nucleosides and nucleoside analogues, pharmaceutical composition and processes for the preparation of the compounds
SE8701605D0 (sv) *	1987-04-16	1987-04-16	Astra Ab	Novel medicinal compounds
US5215970A (en) *	1987-04-16	1993-06-01	Medivir Ab	Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds
GB8712745D0 (en) *	1987-05-30	1987-07-01	Wellcome Found	Antiviral compounds
US4804651A (en) *	1987-06-09	1989-02-14	Board Of Regents, The University Of Texas System	Methods and compositions for the treatment of psoriasis
YU110888A (en) *	1987-06-10	1989-08-31	Wellcome Found	Process for obtaining timine derivatives
US4837311A (en) *	1987-06-22	1989-06-06	Hoffman-La Roche Inc.	Anti-retroviral compounds
USRE33887E (en) *	1987-06-22	1992-04-14	Hoffmann-La Roche Inc.	Anti-retroviral compounds
SU1548182A1 (ru) *	1987-12-29	1990-03-07	Институт молекулярной биологии АН СССР	5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ
GB8800276D0 (en) *	1988-01-07	1988-02-10	Univ Liverpool	Medical treatment
FR2640267B2 (fr) *	1988-01-19	1992-02-14	Univ Paris Curie	Procede de synthese de l'azido-3(prime)-desoxy-3(prime)-thymidine et analogues
FR2626001B1 (fr) *	1988-01-19	1991-11-08	Univ Paris Curie	Procede de synthese de l'azido-3ÿi1ÿ.-desoxy-3ÿi1ÿ.-thymidine et analogues
US4921950A (en) *	1988-06-09	1990-05-01	Burroughs Wellcome Co.	Preparation of 3'azido-3-'-deoxythymidine
US6252060B1 (en)	1988-07-07	2001-06-26	Nexstar Pharmaceuticals, Inc.	Antiviral liponucleosides: treatment of hepatitis B
US5817638A (en) *	1988-07-07	1998-10-06	Nexstar Pharmaceuticals, Inc.	Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en)	1988-07-07	2003-07-29	Chimerix, Inc.	Methods of treating viral infections using antiviral liponucleotides
SE8802687D0 (sv) *	1988-07-20	1988-07-20	Astra Ab	Nucleoside derivatives
FR2635778A1 (fr) *	1988-08-26	1990-03-02	Ire Celltarg Sa	Nouveaux derives de la 3(prime) azido-3(prime) deoxythymidine (azt) actifs contre le virus hiv du sida
IE980216A1 (en) *	1989-04-17	2000-02-23	Scotia Holdings Plc	Anti-virals
HU205089B (en) *	1989-05-31	1992-03-30	Biogal Gyogyszergyar	Process for producing new thymine derivatives and pharmaceutical compositions comprising same
FR2653771B1 (fr) *	1989-10-27	1994-09-23	Univ Paris Curie	Procede de preparation de l'azt (azido-3'-desoxy-3'-thymidine) et de composes apparentes.
FR2656867A1 (fr) *	1990-01-09	1991-07-12	Centre Nat Rech Scient	Nouveau derives de la thymidine, leur preparation et les compositions qui les contiennent.
FR2668153B1 (fr) *	1990-10-22	1995-03-31	Pasteur Merieux Serums Vacc	Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
US5451671A (en) *	1992-07-27	1995-09-19	Ajinomoto Co., Inc.	Method of purifying 2',3'-dideoxynucleosides
WO1994019362A1 (en) *	1993-02-23	1994-09-01	City Of Hope	4-ethoxy 5-fluoro 2'deoxyuridine
US5559101A (en) *	1994-10-24	1996-09-24	Genencor International, Inc.	L-ribofuranosyl nucleosides
JPH10507763A (ja) *	1994-10-24	1998-07-28	ジェネンコアインターナショナルインコーポレーテッド	Ｌ−ピラノシルヌクレオシド

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2134292A1 (en) *	1971-04-30	1972-12-08	Inst Nat Sante Rech Med	Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine

1986
- 1986-03-14 CA CA000504095A patent/CA1285935C/en not_active Expired - Fee Related
- 1986-03-14 AT AT86301896T patent/ATE135011T1/de not_active IP Right Cessation
- 1986-03-14 DK DK118286A patent/DK166805B1/da not_active IP Right Cessation
- 1986-03-14 DE DE3650492T patent/DE3650492T2/de not_active Expired - Fee Related
- 1986-03-14 AU AU54757/86A patent/AU578809B2/en not_active Ceased
- 1986-03-14 IE IE67686A patent/IE73219B1/en not_active IP Right Cessation
- 1986-03-14 EP EP86301896A patent/EP0199451B1/de not_active Expired - Lifetime
- 1986-03-17 JP JP5907386A patent/JPH0723314B2/ja not_active Expired - Lifetime
1988
- 1988-12-12 MY MYPI88001437A patent/MY104069A/en unknown

Also Published As

Publication number	Publication date
CA1285935C (en)	1991-07-09
DK118286D0 (da)	1986-03-14
IE860676L (en)	1986-09-16
DK118286A (da)	1986-09-17
EP0199451A2 (de)	1986-10-29
EP0199451A3 (en)	1990-09-05
IE73219B1 (en)	1997-05-07
AU5475786A (en)	1986-09-18
JPS61257926A (ja)	1986-11-15
DE3650492T2 (de)	1996-10-31
EP0199451B1 (de)	1996-03-06
JPH0723314B2 (ja)	1995-03-15
ATE135011T1 (de)	1996-03-15
AU578809B2 (en)	1988-11-03
DE3650492D1 (de)	1996-04-11
MY104069A (en)	1993-11-30

Legal Events

Date	Code	Title	Description
1993-07-19	B1	Patent granted (law 1993)
2002-10-28	PBP	Patent lapsed

Publication	Publication Date	Title
DK166805B1 (da)	1993-07-19	Threo-isomeren af 3'-azido-3'-deoxythymidin til anvendelse ved behandling af eller profylakse for humane retrovirusinfektioner, anvendelse af forbindelsen til fremstilling af et laegemiddel med naevnte indikation og farmaceutisk praeparat indeholdende forbindelsen
EP0206497B1 (de)	1994-07-20	Therapeutische Nucleoside und deren Herstellung
AP11A (en)	1987-12-22	Antiviral nucleosides.
DK167377B1 (da)	1993-10-25	3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
JPH08501071A (ja)	1996-02-06	１，５−アンヒドロヘキシトールヌクレオシド類似体および該類似体の医薬としての使用
EP0286425B1 (de)	1995-01-11	Therapeutische Nukleoside
EP0285432B1 (de)	1992-11-11	Therapeutische Nukleoside
CA1333391C (en)	1994-12-06	Therapeutic nucleosides
US5559100A (en)	1996-09-24	Methods of treating hepatitis B virus infection with therapeutic nucleosides
EP0306597B2 (de)	2002-10-16	Antivirale Nukleoside
EP0594223B1 (de)	2000-03-01	Kombination therapeutische Nukleoside mit weiteren therapeutisch wirksamen Komponenten.
WO1988009332A1 (en)	1988-12-01	Therapeutic nucleosides
CA1327005C (en)	1994-02-15	Therapeutic nucleosides
US5175274A (en)	1992-12-29	Therapeutic nucleosides
DK175122B1 (da)	2004-06-07	Farmaceutisk præparat omfattende et farmaceutisk acceptabelt derivat af 3'azido-3'-desoxythymidin samt fremgangsmåde til fremstilling deraf
EP0365556A1 (de)	1990-05-02	Nucleosid-analoge.
CA1303032C (en)	1992-06-09	Antiviral nucleosides
CZ18093A3 (en)	1993-06-16	Novel derivatives of phospholipid nucleosides, process of their preparation as well as their use as antiviral medicaments
IE56505B1 (en)	1991-08-14	Antiviral nucleosides
NZ224007A (en)	1991-04-26	3'-azido-3'-deoxythymidine derivatives as antiviral agents